AN2 Therapeutics (ANTX) Other Operating Expenses (2021 - 2022)

AN2 Therapeutics (ANTX) reported Other Operating Expenses of $1.0 million for Q3 2022, up 100.0% quarter-over-quarter from $500000.0 in Q4 2021.

AN2 Therapeutics (ANTX) Other Operating Expenses (2021 - 2022) Analysis & Trends

AN2 Therapeutics (ANTX) has 2 years of Other Operating Expenses data on file, last reported at $1.0 million in Q3 2022.

Other Operating Expenses for Q3 2022 came in at $1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $1.0 million (up 100.0% YoY), and the FY2022 annual result was $1.0 million, up 33.33% from the prior year.
Other Operating Expenses grew to $1.0 million in Q3 2022 per ANTX's latest filing, from $500000.0 in the prior quarter.
Over five years, Other Operating Expenses peaked at $1.0 million in Q3 2022 and troughed at $250000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	AN2 Therapeutics	161.95 Mn	161.95 Mn	-

Download Data